ArticleScience translational medicine2021
Multiple omics study identifies an interspecies conserved driver for nonalcoholic steatohepatitis.
Abstract read
In one paragraph
Article in Science translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Article
- Sesamin Ameliorates High-Sugar, High-Fat Diet-Induced Hepatic Dysfunction via CYP1A2-Mediated Regulation of Lipid Metabolism and Oxidative Stress.Journal of cellular and molecular medicine · 2026Article
- Breakthroughs in diabetic retinopathy diagnosis and treatment using preclinical research models: current progress and future directions.Annals of medicine · 2025Review
- Article
- Arachidonic acid metabolism in metabolic dysfunction-associated steatotic liver disease and liver fibrosis.Hepatology communications · 2025Review
- Experimental Models to Investigate PNPLA3 in Liver Steatosis.Liver international : official journal of the International Association for the Study of the Liver · 2025Review
- The clinical antiprotozoal drug halofuginone promotes weight loss by elevating GDF15 and FGF21.Science advances · 2025Article
- S100P is a ferroptosis suppressor to facilitate hepatocellular carcinoma development by rewiring lipid metabolism.Nature communications · 2025Article
- Potential therapeutic strategies for MASH: from preclinical to clinical development.Life metabolism · 2024Review
- Protein posttranslational modifications in metabolic diseases: basic concepts and targeted therapies.MedComm · 2024Review
- Genetic engineering drives the breakthrough of pig models in liver disease research.Liver research (Beijing, China) · 2024Review
- ACACA reduces lipid accumulation through dual regulation of lipid metabolism and mitochondrial function via AMPK- PPARα- CPT1A axis.Journal of translational medicine · 2024Article
- Hepatic regulator of G protein signaling 14 ameliorates NAFLD through activating cAMP-AMPK signaling by targeting Giα1/3.Molecular metabolism · 2024Article
- Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases.Clinical and molecular hepatology · 2024Review
- RING finger protein 13 protects against nonalcoholic steatohepatitis by targeting STING-relayed signaling pathways.Nature communications · 2023Article
- Iron as a therapeutic target in chronic liver disease.World journal of gastroenterology · 2023Review
- Current, emerging, and potential therapies for non-alcoholic steatohepatitis.Frontiers in pharmacology · 2023Review
- Integrative network-based analysis on multiple Gene Expression Omnibus datasets identifies novel immune molecular markers implicated in non-alcoholic steatohepatitis.Frontiers in endocrinology · 2023Article
- Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic.Frontiers in medicine · 2023Review
- Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention.Cardiovascular diabetology · 2022Review
Corrections and comments
- Commented on by
Authors and funding
34 authors.
Xiao-Jing ZhangDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China.ORCID 0000-0002-8271-7405
Zhi-Gang SheDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China.ORCID 0000-0001-9402-4166
Junyong WangDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China.ORCID 0000-0002-7799-4555
Dating SunDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China.ORCID 0000-0001-6504-4985
Li-Jun ShenDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China.ORCID 0000-0002-8132-2890
Hui XiangDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China.ORCID 0000-0001-9910-697X
Xu ChengDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China.ORCID 0000-0002-1577-7627
Yan-Xiao JiInstitute of Model Animal of Wuhan University, Wuhan 430071, China.ORCID 0000-0002-3401-2427
Yong-Ping HuangInstitute of Model Animal of Wuhan University, Wuhan 430071, China.ORCID 0000-0003-3663-6521
Peng-Long LiInstitute of Model Animal of Wuhan University, Wuhan 430071, China.ORCID 0000-0001-8522-7893
Xia YangDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Yanjie ChengInstitute of Model Animal of Wuhan University, Wuhan 430071, China.ORCID 0000-0001-7684-8946
Jun-Peng MaInstitute of Model Animal of Wuhan University, Wuhan 430071, China.ORCID 0000-0002-6533-2386
Hai-Ping WangDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Yufeng HuInstitute of Model Animal of Wuhan University, Wuhan 430071, China.ORCID 0000-0002-9416-262X
Fengjiao HuInstitute of Model Animal of Wuhan University, Wuhan 430071, China.
Song TianDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China.ORCID 0000-0002-7006-6588
Han TianDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Peng ZhangInstitute of Model Animal of Wuhan University, Wuhan 430071, China.
Guang-Nian ZhaoInstitute of Model Animal of Wuhan University, Wuhan 430071, China.ORCID 0000-0002-3112-7595
Lin WangDepartment of Hepatic Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China.ORCID 0000-0001-5586-3012
Man-Li HuInstitute of Model Animal of Wuhan University, Wuhan 430071, China.ORCID 0000-0001-8318-0454
Qin YangInstitute of Model Animal of Wuhan University, Wuhan 430071, China.ORCID 0000-0003-3415-7084
Li-Hua ZhuDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China.ORCID 0000-0002-1168-8010
Jingjing CaiDepartment of Cardiology, The Third Xiangya Hospital, Central South University, Changsha 410013, China.ORCID 0000-0002-7820-536X
Juan YangDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Xin ZhangInstitute of Model Animal of Wuhan University, Wuhan 430071, China.
Xinliang MaDepartment of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA 19004, USA.ORCID 0000-0002-9041-0876
Qingbo XuCentre for Clinic Pharmacology, The William Harvey Research Institute, Queen Mary University of London, London SE5 9NU, UK.ORCID 0000-0003-2474-8155
Rhian M TouyzBritish Heart Foundation Chair in Cardiovascular Medicine, and Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow G12 8TA, UK.ORCID 0000-0003-0670-0887
Peter P LiuDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ontario K1Y 4W7, Canada.ORCID 0000-0002-3017-1199
Rohit LoombaNAFLD Research Center, Division of Gastroenterology and Epidemiology, University of California, San Diego, San Diego, CA 92093, USA.ORCID 0000-0002-4845-9991
Yibin WangDepartment of Anesthesiology, Cardiovascular Research Laboratories, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.ORCID 0000-0003-0852-0767
Hongliang LiDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China.ORCID 0000-0002-9821-0297
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipotoxicity is a recognized pathological trigger and accelerator of nonalcoholic steatohepatitis (NASH). However, the molecular basis of lipotoxicity-induced NASH remains elusive. Here, we systematically mapped the changes in hepatic transcriptomic landscapes in response to lipotoxic insults across multiple species. Conserved and robust activation of the arachidonic acid pathway, in particular the arachidonate 12-lipoxygenase (
Indexed as
Non-alcoholic Fatty Liver DiseaseAnimalsDisease Models, AnimalLiverLiver CirrhosisMiceMice, Inbred C57BLSwine
Identifiers
PMID
34910546What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.